Appropriate management of immunosuppressive therapy remains one of the
major challenges after lung transplantation. Preoperative therapy con
sists of intravenous azathioprine and oral cyclosporin. Early postoper
ative therapy consists of standard triple immunosuppression with corti
costeroids, azathioprine and either cyclosporin or tacrolimus. Previou
sly, corticosteroids were withheld in the first postoperative week to
allow for healing of the bronchial anastomosis. However, it has been d
emonstrated that corticosteroids can be safely begun immediately posto
peratively and this is done in most centres. Recent clinical trials su
ggest that the use of tacrolimus instead of cyclosporin may result in
fewer episodes of acute cellular rejection and improved graft survival
. However, the majority of centres continue to use cyclosporin, as the
use of tacrolimus requires special laboratory equipment and experienc
e. However, more centres are likely to begin using tacrolimus if data
continues to demonstrate improved graft survival. The use of antilymph
ocyte antibody preparations in the immediate postoperative period has
been found to result in a high incidence of cytomegalovirus infection.
Therefore, most centres restrict the use of antilymphocyte antibody p
reparations to episodes of recurrent acute cellular rejection or refra
ctory chronic rejection. Late postoperative immunosuppression is with
azathioprine 1.0 to 2.0 mg/kg, cyclosporin at a dosage to maintain who
le blood concentrations of 250 to 350 mu g/L (immunofluorescence assay
) and prednisone (usually 10 mg/day). Treatment of rejection episodes
is with corticosteroids (e.g. intravenous methylprednisolone 1 g/day f
or 3 days), antilymphocyte antibody preparations or by switching to ta
crolimus in patients maintained on cyclosporin. The use of aerosolised
immunosuppressants bath to prevent rejection and to decrease systemic
toxicity, and the creation of stable chimaeras by simultaneous lung a
nd bone marrow transplantation, are under investigation.